Eoneren BioNTech: Financial Health And Market Sentiment Amidst Transition Since my December update on the company's potential in oncology, BioNTech (NASDAQ:BNTX) is down another 17%. Due to COVID comparisons, revenue and profit had been on the decline at that time, but I reiterated BioNTech's long-term growth potential. This Wednesday, its stock is trading lower after reporting Q4 earnings, even touching 52-week lows in intraday trading. The article below takes a look at any important changes. Based on a cu ...